After we turn 30, we all lose muscle and strength at the rate of 1% a year. MYOS Corporation intends to reverse that.
MYOS Corporation focuses on the formulation, acquisition, and distribution of nutritional, nutraceutical, physical performance enhancement, and wellness products that focus solely on maintaining or improving the health and performance of muscle tissue. Currently the company has on the market MYO-T12, a dietary supplement product for optimizing biological activity, which is marketed at retail stores like GNC as MYO-X.
Myostatin is a structurally related regulatory protein produced in our bodies that inhibits muscle differentiation and growth which our bodies needed mainly at the time of embryonic development. MYOS Corp.’s products focus on inhibiting the activity of myostatin.
While the company has products appreciated by those seeking to build muscle mass, the company aims to treat sarcopenia. Sarcopenia is the progressive loss of muscle that comes with aging. If a person has problems with at least three of the following conditions, they probably have this degenerative muscle disease: problems in lifting or carrying three pounds, need assistance walking, have trouble rising from a chair, have difficulty climbing a set of stairs, or tendency to fall in the past six months.
The population of people in the United States of age 65 increased from 35 million in the year 2000 to about 40 million people in 2010, and that is expected to grow to 72.1 million people. Estimates suggest 45% of that older population suffer from sarcopenia, which amounts to 18 million people, and that number is expected to rise. Of the 1.5 million older people that end up institutionalized into nursing homes and long-term care facilities, about one third were admitted because of their inability to perform the basic activities of daily living. About 1.5% of total healthcare expenditures, or $18.5 billion, are directly attributable to treating sarcopenia. The U.S. spends $26 billion additionally on people over the age of 65 that lose the ability to perform daily activities.
With no drugs on the market approved by the FDA for treatment of Sarcopenia, a resistance training program and supplements from MYOS under the guidance of a geriatrician can play a major role in treating those that suffer from this condition. MYOS Corp. has an aggressive business and marketing strategy which opens the door to opportunity.
Let us hear your thoughts below:
